in

Moderna soars more than 20% in the stock market after the announcement about its vaccine

American biotech Modern skyrocketed on Wall Street on Monday, with its shares gaining more than a twenty% at the close of the quotations, after announcing that you are going to request authorization to market your vaccine against coronavirus both to the United States Food and Drug Administration (FDA) and the European Medicines Agency.

At the close of business at four in the afternoon, Moderna’s shares gained 20.24%, to stand at $ 152.74.

So far this year, the share of the company based in Cambridge (Massachusetts) has appreciated by 700% and only in November, when the positive news about the tests of the vaccine candidate for the causative pathogen began to arrive of the covid-19, the value has shot up just over 127%.

Read more. Covid-19. The US would start vaccination before Christmas

This Monday, the company reported that it will request approval of the products, after the phase 3 study of the vaccine, which included 30,000 participants, showed an effectiveness of 94.1%, a generally good tolerance and did not identify problems serious security to date.

The phase 3 study exceeded the median 2-month follow-up after vaccination, as required by the FDA for emergency use authorization, Moderna said in a statement.

The company also states that the efficacy of the vaccine against the most serious cases of Covid-19 is one hundred percent.

The first injections can be administered from December 21 if the process runs smoothly and approval is granted, said Stéphane Bancel, executive director of Moderna, in an interview with The New York Times.

According to the pharmacist, the efficacy of the vaccine “was constant” according to age, race and ethnicity, and gender demographics and, although there are continuous reviews, “no serious problems have been identified.”

Moderna says that, based on a previous analysis, the most common adverse reactions when the vaccine was administered included pain at the injection site, fatigue, myalgia, arthralgia, headache and redness where the injection was given.

Shares of Pfizer, the US drugmaker whose vaccine is slightly ahead of Moderna’s for approval, closed up 2.90%. .